Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHA:688566)
China · Delayed Price · Currency is CNY 23.62
-0.08 (-0.34%)
Jun 10, 2026, 3:00 PM CST
SHA:688566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 990.67 | 966.06 | 896.53 | 860.93 | 654.73 | 509.69 |
Other Revenue | 0.01 | 0.01 | - | - | - | - |
| 990.68 | 966.07 | 896.53 | 860.93 | 654.73 | 509.69 | |
Revenue Growth (YoY) | 9.58% | 7.76% | 4.13% | 31.49% | 28.46% | -9.94% |
Cost of Revenue | 103.09 | 101.82 | 95.26 | 97.18 | 76.17 | 62.12 |
Gross Profit | 887.6 | 864.25 | 801.28 | 763.76 | 578.56 | 447.57 |
Selling, General & Admin | 591.92 | 563.08 | 458.54 | 459.86 | 361.56 | 304.65 |
Research & Development | 42.46 | 40.7 | 38.65 | 55.77 | 55.18 | 29.28 |
Other Operating Expenses | 14.68 | 13.51 | 9.77 | 10.47 | 9.24 | 9.1 |
Operating Expenses | 644.66 | 614.66 | 509.22 | 533.31 | 426.71 | 341.26 |
Operating Income | 242.94 | 249.58 | 292.06 | 230.44 | 151.85 | 106.32 |
Interest Expense | -0.21 | -0.27 | -0.13 | -0.11 | -0.38 | - |
Interest & Investment Income | 5.89 | 5.76 | 5.4 | 12.02 | 17.77 | 21.64 |
Other Non Operating Income (Expenses) | -0.01 | -0.11 | -0.11 | -0.14 | -0.07 | -0.11 |
EBT Excluding Unusual Items | 248.61 | 254.97 | 297.21 | 242.22 | 169.18 | 127.85 |
Gain (Loss) on Sale of Investments | -2.72 | -2.64 | -43.29 | -1.9 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.01 | - |
Asset Writedown | -0 | - | - | - | - | - |
Other Unusual Items | 48.32 | 48.81 | -0.56 | 7.16 | 5.37 | 4.71 |
Pretax Income | 294.21 | 301.13 | 253.36 | 247.48 | 174.53 | 132.56 |
Income Tax Expense | 41.71 | 40.14 | 34.39 | 28.71 | 20.27 | 18.22 |
Earnings From Continuing Operations | 252.5 | 261 | 218.98 | 218.77 | 154.26 | 114.35 |
Minority Interest in Earnings | 1.57 | 0.61 | 0.35 | 0.32 | 0.4 | 0.55 |
Net Income | 254.07 | 261.61 | 219.33 | 219.09 | 154.67 | 114.9 |
Net Income to Common | 254.07 | 261.61 | 219.33 | 219.09 | 154.67 | 114.9 |
Net Income Growth | 17.44% | 19.28% | 0.11% | 41.65% | 34.61% | -11.42% |
Shares Outstanding (Basic) | 200 | 200 | 194 | 187 | 186 | 188 |
Shares Outstanding (Diluted) | 200 | 200 | 194 | 187 | 186 | 188 |
Shares Change (YoY) | 1.74% | 2.89% | 3.65% | 0.49% | -1.07% | 11.81% |
EPS (Basic) | 1.27 | 1.31 | 1.13 | 1.17 | 0.83 | 0.61 |
EPS (Diluted) | 1.27 | 1.31 | 1.13 | 1.17 | 0.83 | 0.61 |
EPS Growth | 15.43% | 15.93% | -3.42% | 40.96% | 36.07% | -20.78% |
Free Cash Flow | 70.99 | 133.71 | 40.76 | -197.87 | -141.98 | 66.77 |
Free Cash Flow Per Share | 0.35 | 0.67 | 0.21 | -1.06 | -0.76 | 0.35 |
Dividend Per Share | 0.520 | 0.520 | 0.780 | - | 0.480 | 0.480 |
Dividend Growth | -33.33% | -33.33% | - | - | - | - |
Gross Margin | 89.59% | 89.46% | 89.38% | 88.71% | 88.37% | 87.81% |
Operating Margin | 24.52% | 25.84% | 32.58% | 26.77% | 23.19% | 20.86% |
Profit Margin | 25.65% | 27.08% | 24.46% | 25.45% | 23.62% | 22.54% |
Free Cash Flow Margin | 7.17% | 13.84% | 4.55% | -22.98% | -21.68% | 13.10% |
EBITDA | 262.4 | 267.29 | 302.75 | 241.65 | 164.6 | 119.3 |
EBITDA Margin | 26.49% | 27.67% | 33.77% | 28.07% | 25.14% | 23.41% |
D&A For EBITDA | 19.46 | 17.71 | 10.7 | 11.2 | 12.75 | 12.98 |
EBIT | 242.94 | 249.58 | 292.06 | 230.44 | 151.85 | 106.32 |
EBIT Margin | 24.52% | 25.84% | 32.58% | 26.77% | 23.19% | 20.86% |
Effective Tax Rate | 14.18% | 13.33% | 13.57% | 11.60% | 11.62% | 13.74% |
Revenue as Reported | 990.68 | 966.07 | 896.53 | 860.93 | 654.73 | 509.69 |
Advertising Expenses | - | 225.33 | 161.69 | - | 153.2 | 121.29 |